@article{57426a4b02ee4cf09747db893c00a33e,
title = "Commentary on the endocrine society clinical practice guideline on the “treatment of hypercalcemia of malignancy in adults”",
keywords = "Antiresorptive therapy, Bisphosphonate, Calcimimetics, Calcitonin, Clinical practice guidelines, Denosumab, Evidence-to-decision framework, GRADE methodology, Hypercalcemia of malignancy, Knowledge gaps, Refractory",
author = "{El-Hajj Fuleihan}, Ghada and Drake, {Matthew T.}",
note = "Funding Information: ☆ Developer and Funding organization: Endocrine Society Date of Release: Dec 19, 2022 on line March 2023 in print Volume 108, Issue 3, pages 507-528 https://doi.org/10.1210/clinem/dgac621 Target population: Adults with hypercalcemia of malignancy Stakeholders/health care settings: Endocrinologists, oncologists, internists, family practitioners, emergency physicians, critical care and palliative care experts. Hospitals, outpatient facilities, and hospices Cos-sponsoring organizations: European Society of Endocrinology American Society of Bone and Mineral Research Guideline was shared pre-publication for public comments with members of Endocrine Society Guideline Writing Panel Members: Endocrine Society American Society of Clinical Oncology Ghada El-Hajj Fuleihan (Chair), Mathew T. Drake (Co-Chair), Gregory A. Clines, Mimi I. Hu, Claudio Marcocci, M. Hassan Murad, Thomas Piggott, Catherine Van Poznak, and Joy Y. Wu",
year = "2023",
month = jun,
doi = "10.1016/j.metabol.2023.155553",
language = "English (US)",
volume = "143",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
}